Deal Ticker: Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital on financing round with HAYA Therapeutics

HAYA Therapeutics SA, a biotechnology company pioneering precision RNA-guided medicines, has announced that it has raised $65 million in Series A funding. The financing will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate​ HTX-001​ in heart failure ​and the​​ ​continued expansion of its RNA-guided regulatory genome pipeline development engine. The RNA-guided regulatory genome targets therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. 

The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, ​BERNINA Bioinvest and​ Schroders Capital. 

We are pleased to have advised Sofinnova Partners and Earlybird Venture Capital on all Swiss legal aspects of this financing round by a team led by Nicolas Mosimann (VC/Life Sciences) and comprising Marco Sibold (tax), Kevin MacCabe (Corporate/VC), Sebastian Müller (Corporate/VC), Jan Bläuer (Corporate/VC) and Danijel Gajic (Corporate/VC).  

Congratulations to the team at HAYA Therapeutics SA and the investors on this milestone!